A Discussion on the Coronavirus (SARS-COV-2)

Mar 16, 2020 | Blog | 0 comments

Daniel Gigante

Brett Averso, CTO, and I linked up to discuss the coronavirus (SARS-CoV-2). Brett covered what exactly the coronavirus is, the threat it currently presents (attention given to relative threat with respect to the original SARS virus [SARS-CoV] and MERS [MERS-CoV]), how we can best protect ourselves and our loved ones against infection, and what EVQLV is doing to address the outbreak. Watch our entire discussion below.

The discussion regarding the incubation period is supported by research performed by a Johns Hopkins lead study published in the Annals of Internal Medicine. Our discussion regarding the Case-Fatality Rate (CFR) was provided by the Chinese CDC and published by Jama Network on February 24th. We’ve constructed relevant pie charts based upon their data below.

n = 44672. Data above independent of demographics

For additional tips on how to keep you and your loved ones safe, view the CDC guidelines.

For more information on EVQLV’s work on combatting coronavirus, view Immunoprecise’s press release.

As Brett suggested, we recommend investigating the latest research without the news hype on the coronavirus with Google Scholar. Two examples below.

1. Sars-CoV-2

2. COVID-19


Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology

Demystifying AI In Pharma

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia

EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).

How Our Algorithm Models the Drug Discovery Process

Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

Pin It on Pinterest